Flucytosine (5-Fluorocytosine)

製品コードS1666 バッチS166604

印刷

化学情報

Chemical Structure Synonyms 5-FC, NSC 103805, Ro 2-9915 Storage
(From the date of receipt)		 3 years -20°C powder
1 years -80°C in solvent
化学式

C4H4FN3O
分子量 129.09 CAS No. 2022-85-7
Solubility (25°C)* 体外 DMSO 13 mg/mL (100.7 mM)
Water 7 mg/mL (54.22 mM)
Ethanol Insoluble
体内 （毎回新しく調製した物を用意してください）
Homogeneous suspension
0.5% methylcellulose 0.2% Tween 80
5.0mg/ml Taking the 1 mL working solution as an example, take 5 mg of this product and add it to 1 ml of 0.5% methylcellulose+0.2% Tween 80 clear solution, and mix evenly to form a uniform suspension. The mixed solution should be used immediately for optimal results. 
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

溶剤液（一定の濃度）を調合する

生物活性

製品説明 Flucytosine (5-Fluorocytosine) is an antifungal drug with IC50 of 0.93 μM in C. albicans.
in vitro Flucytosine inhibits the growth of C. neoformans in Sabouraud's dextrose broth at concentrations ≥ 1.25 mg/L, and Flucytosine of 50 mg/L causes a ~50% reduction in colony-forming unit (cfu)\ in the J774.16 killing assay with viability of J774.16 cells not affected measured by trypan blue exclusion. The combination of Flucytosine and IgGl monoclonal antibody to Cryptococcus neoformans capsular glucuronoxylomannan is more effective in reducing the numbers of C. neoformans colony-forming units in vitro with J774.16 murine macrophage-like cells than either agent alone. [2] The efficacy of Flucytosine (5FC) in combination with amphotericin B (AB) and fluconazole (FCZ) is studied against 35 yeast isolates, of which the 5FC-FCZ combination is antagonistic against Candida species, but for some Candida isolates synergism is found. [3]
in vivo Administration of Flucytosine in combination with monoclonal antibody 2H1 to A/JCr mice infected with C. neoformans significantly reduces lung but not brain cfu, which is more effective than either agent alone. [2] The combination of intravenous Flucytosine in 0.9% saline (NaCl) and amphotericin B (AmB) provides synergistic antifungal activity and is associated with a lower incidence of nephrotoxicity than with AmB treatment alone. Infusion of Flucytosine (5-10 mg/kg/min) dissolved in 5% glucose into the renal artery of an in situ perfused kidney for 15 minutes increases renal blood flow (RBF) in the rat, and the renal vasodilatation persists for the duration of the Flucytosine infusion. [4]
特徴 First synthesized in 1957, and antifungal properties discovered in 1964.

プロトコル(参考用のみ)

キナーゼアッセイ Microdilution method
The culture media used are RPMI 1640 with glutamine, without bicarbonate and phenol red, buffered with morpholinopropanesulfonic acid (MOPS) (0.165 M, pH 7.0). Two-fold serial dilutions of Flucytosine (0.06-64 μg/mL) are prepared and dispensed in 50 uL aliquot, in flat-bottom 96-well assay plates which are kept frozen at -70 °C in sealed plastic bags until used. The inoculum is prepared spectrophotometrically and standardized to a concentration of 1.0-5.0 × 103 cfu per mL. A 50 μL volume of this suspension is used to inoculate each well containing 50 μL of the double concentration of Flucytosine to be tested. Once inoculated, each well therefore contains 100 μL of broth favoured over 200 μL to facilitate the agitation of the plates prior to spectrophotometric reading. After an incubation period of 24 and 48 hours at 35 °C, the plates are agitated for 3 minutes at 900 r.p.m. with a shaker and the optical density of the growth in each well is determined with the use of an automatic plate reader set at 495 nm. The inhibitory concentration of IC50 is computed mathematically.
細胞アッセイ 細胞株 J774.16 murine macrophage-like cell line
濃度 Dissolved in PBS, final concentration 50 mg/L
反応時間 24 hours
実験の流れ J774.16 murine macrophage-like cells plated on 96-well tissue culture plates are incubated with 500 u/mL murine recombinant gamma-interferon overnight at 37 °C. The medium is then replaced with fresh medium containing gamma-interferon 500 μ/mL, LPS 3 mg/L, C. neoformans cells 1.6 × 104/well and Flucytosine 50 mg/L. Plates are incubated for 24 hours at 37 °C. Cell supernatants are collected and cells lysed by adding 0.1 mL sterile distilled water to each well, incubating at room temperature for 30 minutes, and then aspirating and ejecting the lysate with a pipette several times to complete cell disruption. Wells are rinsed with PBS (0.1 mL) and the cell supernatant, and lysate and rinse from each well are pooled, vortexed, diluted 1:50, vortexed again and spread on Sabouraud's dextrose agar for the cfu determination
動物実験 動物モデル Male Sprague-Dawley rats
投薬量 5 mg/kg/min
投与方法 In situ renal perfusion at a rate of 0.13 mL/min

Selleckの高級品が、幾つかの出版された研究調査結果（以下を含む）で使われた：

Identification of SARS-CoV-2-induced pathways reveals drug repurposing strategies [ Sci Adv, 2021, 7(27)eabh3032] PubMed: 34193418

長期の保管のために-20°Cの下で製品を保ってください。

人間や獣医の診断であるか治療的な使用のためにでない。

各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。